NUDT5

Entrez Summary: N/A
UniProt Summary: Enzyme that can either act as an ADP-sugar pyrophosphatase in absence of diphosphate or catalyze the synthesis of ATP in presence of diphosphate (PubMed:27257257). In absence of diphosphate, hydrolyzes with similar activities various modified nucleoside diphosphates such as ADP-ribose, ADP-mannose, ADP-glucose, 8-oxo-GDP and 8-oxo-dGDP (PubMed:10567213, PubMed:10722730, PubMed:19699693, PubMed:21389046, PubMed:17052728). Can also hydrolyze other nucleotide sugars with low activity (PubMed:19699693, PubMed:21389046). In presence of diphosphate, mediates the synthesis of ATP in the nucleus by catalyzing the conversion of ADP-ribose to ATP and ribose 5- phosphate. Nuclear ATP synthesis takes place when dephosphorylated at Thr-45 (PubMed:27257257). Nuclear ATP generation is required for extensive chromatin remodeling events that are energy- consuming (PubMed:27257257). Does not play a role in U8 snoRNA decapping activity (By similarity). Binds U8 snoRNA (By similarity). {ECO:0000250|UniProtKB:Q9JKX6, ECO:0000269|PubMed:10567213, ECO:0000269|PubMed:10722730, ECO:0000269|PubMed:17052728, ECO:0000269|PubMed:19699693, ECO:0000269|PubMed:21389046, ECO:0000269|PubMed:27257257}.

Pfam Domains GO Terms

Compound Hit Most Correlated Genes in Chemogenomics Tissues where Essential in the Avana Dataset (DepMap 20Q1)

Screen	Score
Chloramphenicol 20μM R00 exp13	-2.91
Rifampicin 10μM R00 exp32	-2.7
Zebularine 20μM R07 exp423	-2.54
Rotenone 0.07μM R08 exp431	-2.5
Nocodazole 0.02μM R00 exp23	-2.49
Phenformin 20μM R05 exp212	-2.41
UM0131023 0.05μM R05 exp248	-2.41
Mubritinib 0.2μM R01 exp48	-2.3
Nifuroxazide 5μM R03 exp102	-2.3
Alpha-Amanitin 0.5μM R00 exp5	-2.18
S-trityl-L-cysteine 0.5μM R05 exp243	-2.14
Hypoxia 5%O2 R04 exp191	-2.12
Chloramphenicol 2μM R00 exp12	-2.12
2-Methoxyestradiol 0.55μM R07 exp310	-2.08
CB-839 10μM R05 exp224	-2.08
DABN 2μM R00 exp16	-2.08
Actinomycin-D 0.001μM R00 exp3	-2.06
Vinorelbine 0.001μM R05 exp249	-1.95
BAY-598 4μM R05 exp220	-1.94
Citral 50μM R06 exp274	-1.94
iCRT14 30μM R08 exp492	-1.91
Nutlin-3A 1.6μM R06 exp294	-1.88
MK2206 4μM R08 exp504	-1.86
Myriocin 25μM R06 exp293	-1.84
Mubritinib 0.2μM R02 exp65	-1.8
Nifuroxazide 1μM R01 exp51	-1.78
Deguelin 0.05μM R02 exp69	-1.76
Geldanamycin 0.015 to 0.025μM on day4 R07 exp316	-1.75
QNZ 0.01μM R08 exp439	-1.74
Rifampicin 1μM R00 exp31	-1.74
Rapamycin 10μM R00 exp30	-1.73
Cabazitaxel 0.001μM R05 exp223	-1.72
AICAR 240μM R03 exp116	1.7
CR131-b 0.005μM R08 exp474	1.7
Adefovir 20μM R07 exp332	1.72
ONC212 0.15μM R08 exp513	1.77
ML-792 0.2μM R08 exp505	2
BI-6727 0.0125μM R03 exp97	2.05
BI-2536 0.0042μM R03 exp95	2.48
LY2090314 0.003μM R08 exp499	2.58
Thapsigargin 0.005μM R07 exp407	2.58
CB-5083 0.4μM R08 exp468	2.78
Vemurafenib 6.6μM R02 exp89	2.85
Temozolomide 200μM R04 exp189	2.93
Vemurafenib 6.6μM R08 exp434	3.36
6-Thio-2-deoxyguanosine 2μM R06 exp259	8.08

Global Fraction of Cell Lines Where Essential: 0/739

Tissue	Fraction Of Cell Lines Where Essential
1290807.0	0/1
909776.0	0/1
bile duct	0/28
blood	0/28
bone	0/26
breast	0/33
central nervous system	0/56
cervix	0/4
colorectal	0/17
esophagus	0/13
fibroblast	0/1
gastric	0/16
kidney	0/21
liver	0/20
lung	0/75
lymphocyte	0/16
ovary	0/26
pancreas	0/24
peripheral nervous system	0/16
plasma cell	0/15
prostate	0/1
skin	0/24
soft tissue	0/9
thyroid	0/2
upper aerodigestive	0/22
urinary tract	0/29
uterus	0/5

Expression Distribution